In 2011, a new syndrome termed ASIA was defined pointing to the spectrum of the immune-mediated diseases triggered by an adjuvant stimulus. There are many different kinds of adjuvants, such as mercury, aluminium, as well as infectious components that may also have an adjuvant effect.
According to the definition, an adjuvant is a pharmacological or immunological agent that modifies the effect of other agents. Adjuvants are added to boost the immune response in a vaccine, to produce more antibodies.
An adjuvant in the vaccine sounds a good thing, but no it is not always good for some children. Rather, an adjuvant can seriously damage a child’s immune system. If an adjuvant crosses the blood-brain barrier it can cause damage to the central nervous system. A child may suffer from seizures, anxiety disorder, depression, autism, hyperactivity disorder and many other behavioural, psychological and mental disorders. It is a well-established scientific fact that there is a two-way cross-talk between the immune system and the brain, that plays a crucial role in immunoregulation as well as with the function of the brain [1].
By the time children are 4 to 6 years old, in some developed countries, they receive a total of 126 antigenic compounds along with the high amount of aluminium (Al) adjuvants in the vaccines. Most of the vaccines which are administered to the children are not tested for their toxic effects and safety assessments are not carried out because vaccines are not considered as inherently toxic [1].
Although aluminium is a neurotoxin, during a critical period of brain development young children are repeatedly injected with high quantities of aluminium adjuvant from multiple vaccines. This may lead to neurodevelopmental disorder. During postnatal development, a young child’s brain is more permeable to toxins and kidneys are less able to eliminate them. Therefore, young children are at a greater risk than adults of having adverse reactions from aluminium adjuvants in vaccines. Just 2 – 3 immune adjuvants are enough to override the genetic resistance to immunity [1].
Aluminium adjuvants have same immune-stimulating properties in the vaccines as of autoimmune/inflammatory diseases such as arthritis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, chronic fatigue syndrome, lupus, and autism spectrum disorder [1].
Macrophagic myofasciitis (MMF) is a debilitating disease that occurs in some unlucky people after receiving an aluminium-containing vaccine. Aluminium in vaccines may collect from the site of the injection or circulate in the blood, travel to other cells and lymph nodes and thus accumulates in distant organs such as the spleen and the brain [2]. MMF sufferers have symptoms including chronic fatigue, muscle weakness, joint pain, cognitive dysfunction affecting memory and attention, sleep disturbances and disabling headaches. Nearly 20% of patients of MMF develop autoimmune disease [3]. A very interesting yet alarming fact is this, MMF disease can be induced in mice, rats and monkeys by injecting them with the same vaccines, which are given to young children.
There are numerous studies which say aluminium in vaccines can cause autoimmune disorders [4]. Aluminium in vaccines has also been linked to conditions such as arthritis, multiple sclerosis, systemic lupus, Gulf war syndrome, chronic fatigue syndrome, MME, granuloma formation and allergic reactions [5].
Several adjuvants exist in the vaccines, each with specific mechanism, and none of these adjuvants is tested on children before introducing in the vaccine. These adjuvants have the capacity to alter the immune response and risk adverse effects. Therefore, adjuvants in the vaccines such as aluminium and oil-in-water emulsions may cause autoimmune diseases [6].
Vaccine damage due to adjuvants in the vaccines can be reversed with detoxification agents, specific homeopathic remedies and proper use of supplements [7].
References:
- Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012 Feb;21(2):223-30.
- Khan Z et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Medicine volume 11, Article number: 99 (2013).
- Gherardi R K, Authier F. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012 Feb; 21(2): 184–189.
- Shaw C A et al. Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy? Immunotherapy. 2014;6(10):1055-71. doi: 10.2217/imt.14.81.
- Perricone C, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013 Dec;47:1-16. doi: 10.1016/j.jaut.2013.10.004. Epub 2013 Nov 13.
- Pellegrino P, et al. On vaccine’s adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmun Rev. 2015 Oct;14(10):880-8.
- https://www.mindbodyclinic.co.uk/blog/autism-natural-treatments-paced-therapy/